European Disease Progression Monitor: Edition 5

European Disease Progression Monitor: Edition 5

COVID-19 EU progression monitor

lockdown exit strategies in EU

lockdown transition plan

COVID-19 death rate EU

tracking the pandemic

control phase

French data

U.K. numbers have stabilised

Overview of treatments

Disclaimer

For more information, please visit lek.com/covid19 or fill out this form to get in touch.

Other editions in this series:
European Disease progression monitor: Edition 4

Related Insights

Executive Insights

Life Sciences & Pharma

Opportunities for Rare Diseases to Drive Growth in Big Pharma

December 1, 2025

Executive Insights

Life Sciences & Pharma

Behavior-First Biopharma Go-to-Market Strategies

October 6, 2025

Executive Insights

Life Sciences & Pharma

Is Biopharma Doing Enough to Advance Novel Targets?

May 15, 2025

Executive Insights

Life Sciences & Pharma

Transitioning to EU-Wide Health Technology Assessments: Implications for Pharma

April 14, 2025

Life Sciences & Pharma

Unlocking Growth: Singapore's Role in Advancing Life Sciences and Medtech Innovations

March 10, 2025

Executive Insights

Life Sciences & Pharma

Aligning Aseptic Fill/Finish Operations With Global Pharmaceutical Demand

February 3, 2025